Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy



      Disease recurrence is common following prostatectomy in patients with localised prostate cancer with high-risk features. Although androgen deprivation therapy increases the rates of organ-confined disease and negative surgical margins, there is no significant benefit on disease recurrence. Multiple lines of evidence suggest that (Fibroblast Growth Factor/Fibroblast Growth Factor Receptor) FGF/FGFR-signalling is important in supporting prostate epithelial cell survival in hostile conditions, including acute androgen deprivation. Given the recent availability of oral FGFR inhibitors, we investigated whether combination therapy could improve tumour response in the neo-adjuvant setting.


      We conducted an open label phase II study of the combination of erdafitinib (3 months) and androgen deprivation therapy (4 months) in men with localised prostate cancer with high-risk features prior to prostatectomy using a Simon's 2 stage design. The co-primary endpoints were safety and tolerability and pathological response in the prostatectomy specimen. The effect of treatment on residual tumours was explored by global transcriptional profiling with RNA-sequencing.


      Nine patients were enrolled in the first stage of the trial. The treatment combination was poorly tolerated. Erdafitinib treatment was discontinued early in six patients, three of whom also required dose interruptions/reductions. Androgen deprivation therapy for 4 months was completed in all patients. The most common adverse events were hyperphosphataemia, taste disturbance, dry mouth and nail changes. No patients achieved a complete pathological response, although patients who tolerated erdafitinib for longer had smaller residual tumours, associated with reduced transcriptional signatures of epithelial cell proliferation.


      Although there was a possible enhanced anti-tumour effect of androgen deprivation therapy in combination with erdafitnib in treatment naïve prostate cancer, the poor tolerability in this patient population prohibits the use of this combination in this setting.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • McKay RR
        • Feng FY
        • Wang AY
        • Wallis CJD
        • Moses KA
        Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions.
        Am Soc Clin Oncol Educ Book. 2020; 40: 1-12
        • Roh MS
        • Colangelo LH
        • O'Connell MJ
        • et al.
        Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
        J Clin Oncol. 2009; 27: 5124-5130
        • Gleave ME
        • Goldenberg SL
        • Chin JL
        • et al.
        Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
        J Urol. 2001; 166 ([discussion: 6-7.): 500-506
        • Eastham JA
        • Heller G
        • Halabi S
        • et al.
        Cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer.
        J Clin Oncol. 2020; 38: 3042-3050
        • McKay RR
        • Berchuck J
        • Kwak L
        • et al.
        Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials.
        J Urol. 2021; 205: 1689-1697
        • Cmero M
        • Kurganovs NJ
        • Stuchbery R
        • et al.
        Loss of SNAI2 in prostate cancer correlates with clinical response to androgen deprivation therapy.
        JCO Precis Oncol. 2021; 5
        • Lin Y
        • Liu G
        • Zhang Y
        • et al.
        Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis.
        Development. 2007; 134: 723-734
        • Leung HY
        • Mehta P
        • Gray LB
        • Collins AT
        • Robson CN
        • Neal DE.
        Keratinocyte growth factor expression in hormone insensitive prostate cancer.
        Oncogene. 1997; 15: 1115-1120
        • Rajan P
        • Sudbery IM
        • Villasevil ME
        • et al.
        Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
        Eur Urol. 2014; 66: 32-39
        • Schelch K
        • Wagner C
        • Hager S
        • et al.
        FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.
        Carcinogenesis. 2018; 39: 534-545
        • Zhu X
        • Asa SL
        • Ezzat S.
        Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia.
        Clin Cancer Res. 2008; 14: 1984-1996
        • Brown WS
        • Akhand SS
        • Wendt MK.
        FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
        Oncotarget. 2016; 7: 83424-83436
        • Kurimoto R
        • Iwasawa S
        • Ebata T
        • et al.
        Drug resistance originating from a TGF-beta/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
        Int J Oncol. 2016; 48: 1825-1836
        • Sherwin JC
        • Mirmilstein G
        • Pedersen J
        • Lawrentschuk N
        • Bolton D
        • Mills J.
        Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors.
        J Urol. 2010; 183: 1808-1814
        • Cooperberg MR
        • Broering JM
        • Carroll PR.
        Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
        J Natl Cancer Inst. 2009; 101: 878-887
        • Giacomini A
        • Grillo E
        • Rezzola S
        • et al.
        The FGF/FGFR system in the physiopathology of the prostate gland.
        Physiol Rev. 2021; 101: 569-610
        • Janssen T
        • Raviv G
        • Camby I
        • et al.
        In-vitro characterization of dihydrotestosterone-induced, epidermal growth factor-induced and basic fibroblastic growth factor-induced modifications in the growth dynamics of the human prostate-cancer cell-line lncap, du145 and pc3.
        Int J Oncol. 1995; 7: 1219-1225
        • Ozen M
        • Giri D
        • Ropiquet F
        • Mansukhani A
        • Ittmann M.
        Role of fibroblast growth factor receptor signaling in prostate cancer cell survival.
        J Natl Cancer Inst. 2001; 93: 1783-1790
        • da Silva RF
        • Nogueira-Pangrazi E
        • Kido LA
        • et al.
        Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in transgenic adenocarcinoma of the mouse prostate (TRAMP).
        J Biomed Sci. 2017; 24: 31
        • Feng S
        • Shao L
        • Castro P
        • et al.
        Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
        Oncotarget. 2017; 8: 6179-6192
        • Bluemn EG
        • Coleman IM
        • Lucas JM
        • et al.
        Androgen receptor pathway-independent prostate cancer Is sustained through FGF signaling.
        Cancer Cel. 2017; 32 (e6): 474-489
        • Choi YJ
        • Kim HS
        • Park SH
        • Kim BS
        • Kim KH
        • Lee HJ
        • et al.
        Phase II study of dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05).
        Cancer Res Treat. 2018; 50: 1252-1259
        • Gao D
        • Vela I
        • Sboner A
        • et al.
        Organoid cultures derived from patients with advanced prostate cancer.
        Cell. 2014; 159: 176-187
        • Karthaus WR
        • Iaquinta PJ
        • Drost J
        • et al.
        Identification of multipotent luminal progenitor cells in human prostate organoid cultures.
        Cell. 2014; 159: 163-175
        • Cai Y
        • Kregel S
        • Vander Griend DJ
        Formation of human prostate epithelium using tissue recombination of rodent urogenital sinus mesenchyme and human stem cells.
        J Vis Exp. 2013;
        • Hayward SW
        • Haughney PC
        • Rosen MA
        • et al.
        Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model.
        Differentiation. 1998; 63: 131-140
        • Kato M
        • Ishii K
        • Iwamoto Y
        • et al.
        Activation of FGF2-FGFR signaling in the castrated mouse prostate stimulates the proliferation of basal epithelial cells.
        Biol Reprod. 2013; 89: 81
        • Nishi N
        • Oya H
        • Matsumoto K
        • Nakamura T
        • Miyanaka H
        • Wada F.
        Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates.
        Prostate. 1996; 28: 139-152
        • Hetzl AC
        • Montico F
        • Lorencini RM
        • Kido LA
        • Candido EM
        • Cagnon VH.
        Prostatic microenvironment in senescence: fibroblastic growth factors x hormonal imbalance.
        Histochem Cell Biol. 2014; 141: 531-542
        • Loriot Y
        • Necchi A
        • Park SH
        • et al.
        Erdafitinib in locally advanced or metastatic urothelial carcinoma.
        N Engl J Med. 2019; 381: 338-348